natgillin/translations-raw huggingface dataset:
If you have diabetic eye disease and are using insulin, this medicine may lead to a worsening of your vision, and this may require treatment.
Diabetična očesna bolezen (retinopatija) Če imate diabetično očesno bolezen in uporabljate insulin, lahko to zdravilo povzroči poslabšanje vašega vida in zahteva dodatno zdravljenje.
• on its own - if your blood sugar is not controlled well enough by diet and exercise alone, and you cannot use metformin (another diabetes medicine) or
• sámo, če krvni sladkor z dieto in s telesno vadbo ni dovolj urejen in ne morete jemati metformina (drugega zdravila za zdravljenje sladkorne bolezni), ali
In addition, semaglutide reduces the preference for high fat foods.
Poleg tega semaglutid zmanjša nagnjenost k uživanju zelo mastne hrane.
• less appetite
• slabši apetit
• Before you use the pen for the first time, your doctor or nurse will show you how to use it.
• Preden prvič uporabite injekcijski peresnik, vam bo zdravnik ali medicinska sestra pokazal/a, kako ga uporabljate.
3 ml (4 doses)
3 ml (4 odmerki)
For diastolic blood pressure, there were no significant differences between semaglutide and comparators.
Kar zadeva diastolični krvni tlak, med semaglutidom in primerjalnimi zdravili ni bilo značilnih razlik.
They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.
Obsegajo lahko hladen znoj, hladno bledo kožo, glavobol, hiter srčni utrip, slabost (navzeo) ali hudo lakoto, spremembe vida, občutek zaspanosti ali šibkosti, živčnost, tesnobo ali zmedenost, težave z zbranostjo ali tresenje.
The glucose and appetite effects are specifically mediated via GLP-1 receptors in the pancreas and the brain.
Učinki na glukozo in apetit potekajo specifično preko receptorjev GLP-1 v trebušni slinavki in možganih.
In lactating rats, semaglutide was excreted in milk.
Pri doječih podganah se je semaglutid izločal v mleko.
The effect of semaglutide on fertility in humans is unknown.
Vpliv semaglutida na plodnost pri človeku ni znan.
• Check the name and coloured label of your pen, to make sure that it contains Ozempic.
• Preverite ime in barvno nalepko injekcijskega peresnika in se tako prepričajte, da vsebuje zdravilo Ozempic.
This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar.
To mu bo pomagalo pri presoji, ali je treba odmerek sulfonilsečnine ali insulina spremeniti, da bi zmanjšali tveganje za prenizek krvni sladkor.
Do not use this medicine if you notice that the solution is not clear and colourless or almost colourless.
Tega zdravila ne uporabite, če opazite, da raztopina ni bistra in brezbarvna ali skoraj brezbarvna.
If blood appears at the injection site, press lightly.
Če se na mestu injiciranja pojavi kri, nanj rahlo pritisnite.
OTHER SPECIAL WARNINGS, IF NECESSARY Do not store the pen with a needle attached.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Ne shranjujte injekcijskega peresnika z nameščeno iglo.
If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day.
Če je od izpuščenega odmerka minilo že več kot 5 dni, je treba izpuščeni odmerek preskočiti in naslednji odmerek injicirati na redni dan po urniku.
*human glucagon-like peptide-1 (GLP-1) analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology.
*Analog humanega glukagonu podobnega peptida-1 (GLP-1 - glucagon-like peptide-1), pridobljen iz Saccharomyces cerevisiae s tehnologijo rekombinantne DNA.
• complications of diabetic eye disease (retinopathy) - you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine.
• zapleti diabetične očesne bolezni (retinopatije); obvestite zdravnika, če med zdravljenjem s tem zdravilom opazite težave z očmi, na primer spremembe vida
Approximately 3% of the dose was excreted as intact semaglutide via urine.
Približno 3 % odmerka se je izločilo v urinu kot nespremenjeni semaglutid.
The most frequently reported adverse reactions in clinical trials were gastrointestinal disorders, including nausea (very common), diarrhoea (very common) and vomiting (common).
Najpogosteje opisani neželeni učinki v kliničnih preskušanjih so bile prebavne motnje, vključno z navzeo (zelo pogosto), drisko (zelo pogosto) in bruhanjem (pogosto).
The trial population was distributed by age as: 1,598 patients (48.5%) ≥65 years, 321 (9.7%) ≥75 years, and 20 (0.6%) ≥85 years.
Starostna porazdelitev populacije v preskušanju je bila naslednja: 1.598 bolnikov (48,5 %) starih ≥ 65 let, 321 (9,7 %) bolnikov starih ≥ 75 let in 20 (0,6 %) bolnikov starih ≥ 85 let.
Tell your doctor if you have diabetic eye disease or if you experience eye problems during treatment with this medicine.
Zdravnika morate obvestiti, če imate diabetično očesno bolezen, ali če se vam med zdravljenjem s tem zdravilom pojavijo težave z vidom.
Ozempic is used:
Zdravilo Ozempic se uporablja:
If you do that, you might not get the intended effect of this medicine.
Če to storite, morda ne boste deležni želenega učinka tega zdravila.
Do not attach a new needle to your pen until you are ready to take your injection.
Na injekcijski peresnik ne pritrjujte nove igle, dokler niste pripravljeni na injiciranje zdravila.
Therapeutic experience in patients ≥75 years of age is limited (see section 5.2).
Izkušnje z zdravljenjem bolnikov, starih 75 let ali več, je malo (glejte poglavje 5.2).
Frequent blood testing to determine the ability of your blood to clot may be required.
Morda bo potrebno opraviti več preiskav krvi, da se oceni sposobnost vaše krvi za tvorjenje krvnega strdka.
In a study with a single subcutaneous dose of radiolabelled semaglutide, it was found that the primary excretion routes of semaglutide-related material were via urine and faeces; approximately 2/3 of semaglutide-related material were excreted in urine and approximately 1/3 in faeces.
V študiji enkratnega subkutanega odmerka radioaktivno označenega semaglutida so ugotovili, da sta primarni poti izločanja semaglutidu podobnih spojin urin in blato; približno 2/3 teh spojin sta se izločili v urinu in približno 1/3 v blatu.
Gender, race (White, Black or African-American, Asian) and ethnicity (Hispanic or Latino, nonHispanic or -Latino) had no effect on the pharmacokinetics of semaglutide.
Spol, rasa in etnično poreklo Spol, rasa (bela rasa, črna rasa, Azijci) in etnično poreklo (latinskoameriško poreklo v primerjavi z ne latinskoameriškim poreklom) niso vplivali na farmakokinetiko semaglutida.
Intent-to-Treat (ITT) Population (N)
Populacija z namenom zdravljenja (ITT - intent-to-treat) (N)
What you need to know before you use Ozempic Do not use Ozempic:
Kaj morate vedeti, preden boste uporabili zdravilo Ozempic Ne uporabljajte zdravila Ozempic:
All pharmacodynamic evaluations were performed after 12 weeks of treatment (including dose escalation) at steady state with semaglutide 1 mg once weekly.
Vse farmakodinamične ocene so opravili po 12 tednih zdravljenja (vključno s povečanjem odmerka) v stanju dinamičnega ravnovesja z 1 mg semaglutida enkrat na teden.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, but other mechanisms cannot be excluded.
Prehodno poslabšanje diabetične retinopatije povezujejo s hitrim izboljšanjem urejenosti glikemije, vendar drugih vzrokov ni mogoče izključiti.
In foetuses, major skeletal and visceral malformations were observed, including effects on long bones, ribs, vertebrae, tail, blood vessels and brain ventricles.
Pri plodovih so opažali večje skeletne in visceralne malformacije, vključno z učinki na dolge kosti, rebra, vretenca, rep, žile in možganske prekate.
Consistent with the potentially immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide.
Skladno z možnimi imunogenimi lastnostmi zdravil, v katerih so beljakovine ali peptidi, se lahko po zdravljenju s semaglutidom pri bolnikih pojavijo protitelesa.
The frequencies of the adverse reactions are based on a pool of the phase 3a trials excluding the cardiovascular outcomes trial (see text below the table for additional details).
Pogostnosti neželenih učinkov temeljijo na pojavnosti v preskušanjih faze 3a, izključujoč preskušanje srčno-žilnih izidov (za dodatne podrobnosti glejte besedilo pod preglednico).
The rodent C-cell tumours are caused by a non-genotoxic, specific GLP-1 receptor mediated mechanism to which rodents are particularly sensitive.
Tumorje parafolikularnih celic pri glodalcih povzroča negenotoksičen, specifičen mehanizem preko receptorjev GLP-1, za katerega so glodalci posebno občutljivi.
Steady state exposure was achieved following 4-5 weeks of once weekly administration.
Izpostavljenost v stanju dinamičnega ravnovesja je bila dosežena po 4 do 5 tednih injiciranja enkrat na teden.
The hazard ratio [95% CI] for time to nephropathy (new onset of persistent macroalbuminuria, persistent doubling of serum creatinine, need for continuous renal replacement therapy and death due to renal disease) was 0.64 [0.46; 0.88] driven by new onset of persistent macroalbuminuria.
Razmerje ogroženosti [95 % IZ] za čas do nefropatije (novonastala perzistentna makroalbuminurija, perzistentna podvojitev vrednosti serumskega kreatinina, potreba po stalnem nadomestnem ledvičnem zdravljenju in smrt zaradi bolezni ledvic) je bilo 0,64 [0,46; 0,88]; glavni razlog je bila novonastala perzistentna makroalbuminurija.
• Warfarin or other similar medicines taken by mouth to reduce blood clotting (oral anti coagulants).
• varfarin ali druga podobna peroralna zdravila proti strjevanju krvi (peroralne antikoagulante).
Always watch the dose counter to know how many mg you inject.
Vedno glejte števec odmerka, da boste vedeli, koliko miligramov injicirate.
Ozempic should not be used if it has been frozen.
Zdravila Ozempic se ne sme uporabiti, če je bilo zamrznjeno.
Clear and colourless or almost colourless, isotonic solution; pH=7.4.
Bistra, brezbarvna ali skoraj brezbarvna izotonična raztopina s pH 7,4.
In-use shelf life: 6 weeks.
Po prvi uporabi: 6 tednov.
The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.
Mehanizem zniževanja glukoze v krvi vključuje tudi manjšo upočasnitev praznjenja želodca v zgodnji postprandialni fazi.
Beta-cell function and insulin secretion
Delovanje celic beta in izločanje insulina
For use by one person only.
Izključno za uporabo pri enem samem bolniku.
Your doctor may ask you to test your blood sugar levels.
Zdravnik vam bo morda naročil, da si merite koncentracijo krvnega sladkorja.
The efficacy and safety of Ozempic 0.5 mg and 1 mg once weekly were evaluated in six randomised controlled phase 3a trials that included 7,215 patients with type 2 diabetes mellitus (4,107 treated with semaglutide).
Učinkovitost in varnost zdravila Ozempic 0,5 mg in 1 mg enkrat na teden so ocenili v šestih randomiziranih kontroliranih preskušanjih faze 3a, ki so zajela 7.215 bolnikov s sladkorno boleznijo tipa 2 (4.107 zdravljenih s semaglutidom).
Both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.
Izboljšanje uravnavanja glikemije in zmanjšanje obolevnosti in umrljivosti zaradi srčno-žilnih dogodkov sta neločljiva sestavna dela zdravljenja sladkorne bolezni tipa 2.
If there is still no drop, change the needle and repeat step 2 ‘Check the flow' once more.
Če se kapljica še vedno ne pojavi, zamenjajte injekcijsko iglo in še enkrat ponovite korake pod točko 2, "Preverjanje pretoka".
The enzyme neutral endopeptidase (NEP) is expected to be involved in the metabolism of semaglutide.
Domneva se, da je v presnovo semaglutida vključen encim nevtralna endopeptidaza (NEP).
Select your dose
Izberite odmerek
• You can keep the pen for 6 weeks when stored at a temperature below 30°C or in a refrigerator
• Injekcijski peresnik lahko shranjujete 6 tednov pri temperaturi do 30 °C ali v hladilniku (2 °C
These other medicines may include: oral antidiabetics (such as metformin, thiazolidinediones, sulfonylureas) or insulin.
Med temi zdravili so lahko peroralni antidiabetiki (npr. metformin, tiazolidindioni, sulfonilsečnine) ali insulin.
• fast pulse
• hiter srčni utrip
• Do not inject Ozempic which has been frozen.
• Ne injicirajte zdravila Ozempic, ki je bilo zmrznjeno.
Semaglutide doses of 0.5 mg and 1 mg provide adequate systemic exposure over a body weight range of 40-198 kg.
Odmerka semaglutida 0,5 mg in 1 mg zagotovita ustrezno sistemsko izpostavljenost v razponu telesne mase od 40 do 198 kg.
For further information on administration, see section 6.6.
Za dodatne informacije o apliciranju zdravila glejte poglavje 6.6.
1.5 ml (4 doses)
1,5 ml (4 odmerki)
• The active substance is semaglutide.
• Učinkovina je semaglutid.
When Ozempic is added to existing metformin and/or thiazolidinedione therapy, the current dose of metformin and/or thiazolidinedione can be continued unchanged.
Če je zdravilo Ozempic dodano obstoječemu zdravljenju z metforminom in/ali tiazolidindioni, je mogoče metformin in/ali tiazolidindione še naprej uporabljati v nespremenjenem odmerku.
During treatment with this medicine, you may feel sick (nausea) or be sick (vomiting), or have diarrhoea.
Med zdravljenjem s tem zdravilom se vam lahko pojavi slabost (navzea), lahko bruhate ali imate drisko.
• Always keep your pen and needles out of the sight and reach of others, especially children.
• Injekcijski peresnik in igle vedno shranjujte nedosegljive drugim, zlasti otrokom.
However, a direct effect of semaglutide on the foetus cannot be excluded.
Neposrednega učinka semaglutida na plod kljub temu ni mogoče izključiti.
Other medicines and Ozempic
Druga zdravila in zdravilo Ozempic
If the paper tab is broken, do not use the needle, as sterility is not guaranteed.
Če je papirna nalepka poškodovana ali pretrgana, injekcijske igle ne uporabite, ker njena sterilnost v tem primeru ni zagotovljena.
No other treatment-related tumours were observed.
Drugih tumorjev, povezanih z zdravljenjem s tem zdravilom, niso opazili.
Compared to native GLP-1, semaglutide has a prolonged half-life of around 1 week making it suitable for once weekly subcutaneous administration.
V primerjavi z naravnim GLP-1 ima semaglutid daljši razpolovni čas (približno 1 teden), zato je primeren za subkutano apliciranje enkrat na teden.
There is no experience in patients with congestive heart failure NYHA class IV and semaglutide is therefore not recommended in these patients.
Izkušenj pri zdravljenju bolnikov s srčnim popuščanjem razreda IV po razvrstitvi New York Heart Association (NYHA) ni in zato uporaba semaglutida pri teh bolnikih ni priporočljiva.
Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
Semaglutid deluje kot agonist receptorja GLP-1 ter se selektivno veže in aktivira receptor GLP-1, ki je tarča naravnega GLP
1.5 ml or 3 ml glass cartridge (type I glass) closed at the one end with a rubber plunger (chlorobutyl) and at the other end with an aluminium cap with a laminated rubber sheet (bromobutyl/polyisoprene) inserted.
1,5-ml ali 3-ml steklen vložek (steklo tipa I), na eni strani zaprt z gumijastim batom (klorobutil) in na drugi strani z aluminijastim pokrovčkom z vstavljeno plastjo laminirane gume (bromobutil/poliizopren).
A 2-year clinical trial investigated 3,297 patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose.
V 2-letnem kliničnem preskušanju so preučili 3.297 bolnikov s sladkorno boleznijo tipa 2 z velikim srčno-žilnim tveganjem, dolgotrajno sladkorno boleznijo in slabo urejeno glikemijo.
Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia.
Bolniki, ki prejemajo semaglutid skupaj s sulfonilsečnino ali insulinom, imajo lahko večje tveganje za hipoglikemijo.
If a dose is missed, it should be administered as soon as possible and within 5 days after the missed dose.
V primeru izpuščenega odmerka je treba odmerek injicirati čim prej, znotraj 5 dni po izpuščenem odmerku.
• it is 5 days or less since you should have used Ozempic, use it as soon as you remember.
• je od izpuščenega odmerka zdravila Ozempic minilo 5 dni ali manj, zdravilo uporabite takoj ko se spomnite.
If a drop still does not appear, dispose of the pen and use a new one.
Če kapljice še vedno ni, injekcijski peresnik zavrzite in uporabite novega.
The total number of primary component MACE endpoints was 254, including 108 (6.6%) with semaglutide and 146 (8.9%) with placebo.
Skupno število primarnih opazovanih dogodkov MACE je bilo 254, od teh 108 (6,6 %) med prejemniki semaglutida in 146 (8,9 %) med prejemniki placeba.
• Do not expose your pen to dust, dirt or liquid.
• Injekcijskega peresnika ne izpostavljajte prahu, umazaniji ali tekočinam.
Your doctor may reduce your dose of these medicines before you start using this medicine.
Zdravnik lahko pred uvedbo zdravljenja z zdravilom Ozempic odmerek teh zdravil zmanjša.
During induced hypoglycaemia, semaglutide compared to placebo did not alter the counter regulatory responses of increased glucagon and did not impair the decrease of C-peptide in patients with type 2-diabetes.
Med inducirano hipoglikemijo semaglutid v primerjavi s placebom ni spremenil protiregulacijskih odzivov zvišanja koncentracije glukagona ter ni okrnil znižanja koncentracije C-peptida pri bolnikih s sladkorno boleznijo tipa 2.
MedDRA system organ class
MedDRA organski sistem
• The starting dose is 0.25 mg once a week for four weeks.
• Začetni odmerek je 0,25 mg enkrat na teden za obdobje štirih tednov.
• you develop diabetic ketoacidosis - a complication of diabetes with high blood sugar, breathing difficulty, confusion, excessive thirst, a sweet smell to the breath or a sweet or metallic taste in the mouth.
• če se vam pojavi diabetična ketoacidoza; to je zaplet sladkorne bolezni z visokim sladkorjem v krvi, težkim dihanjem, zmedenostjo, hudo žejo, sladkobnim zadahom in sladkim ali kovinskim okusom v ustih.
Semaglutide did not change the overall exposure or Cmax of metformin following dosing of 500 mg twice daily over 3.5 days.
Semaglutid ni spremenil celotne izpostavljenosti metforminu ali njegove Cmax po uporabi 500 mg paracetamola dvakrat na dan v obdobju 3,5 dneva.
There is no specific antidote for overdose with semaglutide.
Specifičnega protistrupa za preveliko odmerjanje semaglutida ni.
This was shown with a single dose of 0.5 mg semaglutide for patients with different degrees of renal impairment (mild, moderate, severe or patients in dialysis) compared with subjects with normal renal function.
To je bilo dokazano z enkratnim odmerkom 0,5 mg semaglutida pri bolnikih z različnimi stopnjami okvare ledvic (blaga, zmerna, huda ali bolniki na dializi) v primerjavi z osebami z normalnim delovanjem ledvic.
There are limited data from the use of semaglutide in pregnant women.
Podatkov o uporabi semaglutida pri nosečnicah je malo.
• Caregivers must be very careful when handling used needles to prevent needle injury and cross infection.
• Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami zelo pazljive, da se ne bi zbodle in okužile.
There were 2,358 patients with normal or mild renal impairment, 832 with moderate and 107 with severe or end stage renal impairment.
Normalno delovanje ledvic ali blago okvaro ledvic je imelo 2.358 bolnikov, zmerno okvaro 832 bolnikov in hudo okvaro ali končno odpoved ledvic 107 bolnikov.
Inject your dose
Injicirajte odmerek
The findings coincided with marked maternal body weight loss of up to 16%.
Ti izsledki so sovpadali z izrazitim zmanjšanjem telesne mase samic do 16 %.
Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life (see section 5.2).
Zaradi dolgega razpolovnega časa je treba semaglutid prenehati uporabljati vsaj 2 meseca pred načrtovano nosečnostjo (glejte poglavje 5.2).
The European Medicines Agency has deferred the obligation to submit the results of studies with semaglutide in one or more subsets of the paediatric population in type 2 diabetes (see section 4.2).
Evropska agencija za zdravila (EMA) je začasno odložila obvezo za predložitev rezultatov študij s semaglutidom za vse podskupine pediatrične populacije za sladkorno bolezen tipa 2 (glejte poglavje
Your pen is designed to be used with NovoFine and NovoTwist disposable needles up to a length of 8 mm.
Injekcijski peresnik je namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm.
If no drop appears, repeat step 2 ‘Check the flow' up to 6 times.
Če se kapljica ne pojavi, do 6-krat ponovite korake pod točko 2, "Preverjanje pretoka".
Severe hypoglycaemia was primarily observed when semaglutide was used with a sulfonylurea (1.2% of subjects, 0.03 events/patient year) or insulin (1.5% of subjects, 0.02 events/patient year).
Hude hipoglikemije so bile opisane predvsem v primerih, ko je bil semaglutid uporabljen s sulfonilsečnino (1,2 % bolnikov, 0,03 primera/bolnik-leto) ali z insulinom (1,5 % bolnikov, 0,02 primera/bolnik-leto).
In clinical trials up to 1 year involving 4,807 patients with type 2 diabetes, adverse events related to diabetic retinopathy were reported in similar proportions of subjects treated with semaglutide (1.7%) and comparators (2.0%).
V kliničnih preskušanjih, ki so trajala do 1 leto in so vključevala 4.807 bolnikov s sladkorno boleznijo tipa 2, so o neželenih učinkih, povezanih z diabetično retinopatijo, poročali pri podobnem deležu bolnikov, zdravljenih s semaglutidom (1,7 %), in bolnikov, ki so prejemali primerjalna zdravila
(2°C - 8°C) away from the cooling element.
8 °C) ter proč od zamrzovalnega razdelka.
• Keep the needle in your skin after the dose counter has returned to 0 and count slowly to 6.
• Ko se števec odmerka vrne na 0, pustite iglo v koži in počasi preštejte do 6.
• The best places to give the injection are the front of your thighs, the front of your waist
• Najprimernejša mesta za injiciranje so sprednji del stegna, sprednji del trebuha ali nadlaket.
Most events were mild to moderate in severity and of short duration.
Večina teh učinkov je bila blagih do zmernih in so bili kratkotrajni.
With semaglutide, the insulin secretion rate in patients with type 2 diabetes was comparable to that of healthy subjects.
S semaglutidom je bila hitrost izločanja insulina pri bolnikih s sladkorno boleznijo tipa 2 primerljiva tisti pri zdravih osebah.
Flow check symbol selected
izbran je simbol za preverjanje pretoka
Semaglutide should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption.
Semaglutid je treba uporabljati previdno pri bolnikih, zdravljenih s peroralnimi zdravili, ki zahtevajo hitro absorpcijo iz prebavil.
In patients with type 2 diabetes clearance of semaglutide was approximately 0.05 L/h.
Pri bolnikih s sladkorno boleznijo tipa 2 je bil očistek semaglutida približno 0,05 l/h.
If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help.
Če ste slepi ali slabovidni in ne morete odčitati števca odmerka na injekcijskem peresniku, sami ne uporabljajte injekcijskega peresnika.
Systematic evaluation of diabetic retinopathy complication was only performed in the cardiovascular outcomes trial.
Zapleti diabetične retinopatije so bili sistematično ovrednoteni le v sklopu preskušanja srčno-žilnih izidov.
However, upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.
Vseeno je pri bolnikih, ki jemljejo varfarin ali druge kumarinske derivate, po uvedbi semaglutida priporočljivo pogosto nadzirati INR.